Abeona Therapeutics Inc

$4.97

(as of Mar 28, 3:50 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Abeona Therapeutics Inc

Stock Price

$4.97

Ticker Symbol

ABEO

Exchange

NASDAQ

Industry Information for Abeona Therapeutics Inc

Sector

Healthcare

Industry

Biotechnology

Company Description for Abeona Therapeutics Inc

Website

https://www.abeonatherapeutics.com

Country

USA

Full Time Employees

136

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Fundamentals for Abeona Therapeutics Inc

Market Capitalization

$241,212,976

EBITDA

$-62,207,000

Dividends per Share

P/E Ratio

Forward P/E Ratio

Earnings per Share

$-1.55

Earnings per Share Estimate Next Year

Profit Margin

Shares Outstanding

48,533,800

Percent Owned by Insiders

4.88%

Percent Owned by Institutions

68.52%

52-Week High

52-Week Low

Technical Indicators for Abeona Therapeutics Inc

50-Day Moving Average

200-Day Moving Average

RSI

ATR

0.26

Analyst Ratings for Abeona Therapeutics Inc

Strong Buy

Buy

Hold

Sell

Strong Sell

News About Abeona Therapeutics Inc

Mar 20, 2025, 7:30 AM EST

FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 See more.